Gilead Sciences (GILD) 117.78 $GILD
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Business Wire - Tue Jul 21, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2015 and provide a general business update.
GILD: 117.78 (-0.42)
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Business Wire - Tue Jul 21, 1:06PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session (session TUAB0102) at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS) in Vancouver, Canada.
GILD: 117.78 (-0.42)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Gilead Sciences (GILD) Approaches New Downside Target of $117.22
Comtex SmarTrend(R) - Tue Jul 21, 11:06AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $118.33 today and has reached the first level of support at $117.71. Should the shares continue to fall, the support pivots of $117.22 and $116.11 will be of interest.
GILD: 117.78 (-0.42)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
The Best Deals in Value Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 8:04AM CDT
Source: Federal Reserve Bank of New York via Facebook Investors may have suffered through the worst case of stock market "indigestion" in multiple generations between 2007 and 2009, but the subsequent bull market has produced some of the most...
F: 14.51 (-0.06), IBM: 163.07 (-10.15), GILD: 117.78 (-0.42), BAC: 18.08 (-0.04), AAPL: 130.75 (-1.32)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 117.78 (-0.42), VKTX: 6.76 (+0.12)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
Critical Alerts For Linn Energy, Gilead Sciences, BP, Alcoa and Opko Health Released By InvestorsObserver
PR Newswire - Mon Jul 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, GILD, BP, AA and OPK.
AA: 10.23 (+0.03), OPK: 16.14 (-0.20), GILD: 117.78 (-0.42), BP: 38.73 (-0.02), LINE: 6.09 (+0.06)
Research and Markets: Key Pharma News Issue - Gilead will make further oncology deals in 2015
Business Wire - Mon Jul 20, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fz2fmj/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering.
GILD: 117.78 (-0.42)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 187.07 (-0.57), GILD: 117.78 (-0.42), MRK: 58.67 (-0.33), ASPX: 100.96 (unch), NVS: 103.71 (-2.41)
Gilead's Fantastic Growth Expected To Slow
at Investor's Business Daily - Fri Jul 17, 5:48PM CDT
With nearly 400 companies in IBD's biotech industry group, it takes a lot to stand out, and Gilead Sciences (GILD) is doing that with its profit growth. The company's three-year average earnings growth rate of 74% is sixth highest, and its 2014 EPS...
GILD: 117.78 (-0.42), ABBV: 70.54 (-0.26)
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:30PM CDT
Bristol-Myers Squibb Company (BMY) announced that the European Commission has approved Evotaz.
EBIO: 2.95 (-0.04), GILD: 117.78 (-0.42), ANAC: 149.31 (+1.18), BMY: 68.87 (-1.10)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 123.98 (+1.04), AGN: 317.00 (-0.75), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), UTHR: 175.17 (-2.34), RCPT: 228.98 (+0.26), MOH: 72.56 (-0.42), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01)
Gilead Sciences (GILD) Breaks Through Resistance at $119.00
Comtex SmarTrend(R) - Thu Jul 16, 11:49AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $118.11 today and have reached the first resistance level of $119.00. Investors may be interested in a cross of the next upside pivot targets of $120.62 and $123.13.
GILD: 117.78 (-0.42)
Fitbit Leads Trio Of Hot Health-Related IPO Stocks
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
New analyst coverage and a big Celgene deal helped give a healthy boost to hot new issue Fitbit (FIT) and a pair of recent biotech IPOs Wednesday. Fitbit hit a second straight new high as it continues its hot streak. The June 18 IPO, which ran up 48%...
FIT: 46.87 (+2.40), GILD: 117.78 (-0.42), XON: 56.77 (-1.18), RCPT: 228.98 (+0.26), ABBV: 70.54 (-0.26), ENTA: 49.27 (-0.17), CELG: 136.24 (+1.01)
What Will Gilead Buy Next? 4 Possible Targets
at Investor's Business Daily - Wed Jul 15, 3:44PM CDT
Tuesday's announcement that Celgene (CELG) agreed to acquire Receptos (RCPT) pleased investors in those two stocks, but for investors in Gilead Sciences (GILD), which was rumored to be interested in Receptos, it means waiting on the edges of their...
JNJ: 100.34 (-0.03), VRTX: 130.97 (-2.50), GILD: 117.78 (-0.42), ACHN: 9.26 (-0.10), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), BMY: 68.87 (-1.10), CELG: 136.24 (+1.01)
Are Gilead Sciences, Inc.'s Expectations Too High for This Drug?
Keith Speights, The Motley Fool - Motley Fool - Wed Jul 15, 11:03AM CDT
Source: Gilead Sciences. Like the mythical King Midas, it seems that nearly everything Gilead Sciences touches turns to gold -- maybe that's where it gets its ticker symbol. The big biotech has built a juggernaut over the years from its HIV drug...
GILD: 117.78 (-0.42)
Celgene Hits High As Street Applauds Receptos Buyout
at Investor's Business Daily - Wed Jul 15, 10:12AM CDT
Celgene (CELG) stock jumped 10% to a new high above 135 Wednesday morning as it got several price-target increases in the wake of its deal to buy Receptos (RCPT). Celgene agreed to pay $7.2 billion for Receptos and announced preliminary Q2 earnings...
BIIB: 409.50 (+0.57), GILD: 117.78 (-0.42), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), LLY: 85.57 (-2.30), TEVA: 63.35 (-0.26), ARNA: 4.30 (-0.05), CELG: 136.24 (+1.01)
Stock Market News for July 15, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 9:10AM CDT
Gains in energy shares amid a rise in oil prices helped benchmarks end higher on Tuesday
JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), JPM: 69.10 (-0.16), RIG: 13.35 (unch), GILD: 117.78 (-0.42), AMGN: 163.70 (-0.64), COP: 56.49 (-0.08), XOM: 81.66 (-0.10), WFC: 57.95 (-0.10), CVX: 93.90 (+0.96), SLB: 84.30 (+0.78), CELG: 136.24 (+1.01)
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Business Wire - Tue Jul 21, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2015 and provide a general business update.
GILD: 117.78 (-0.42)
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Business Wire - Tue Jul 21, 1:06PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session (session TUAB0102) at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS) in Vancouver, Canada.
GILD: 117.78 (-0.42)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Gilead Sciences (GILD) Approaches New Downside Target of $117.22
Comtex SmarTrend(R) - Tue Jul 21, 11:06AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $118.33 today and has reached the first level of support at $117.71. Should the shares continue to fall, the support pivots of $117.22 and $116.11 will be of interest.
GILD: 117.78 (-0.42)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
The Best Deals in Value Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 8:04AM CDT
Source: Federal Reserve Bank of New York via Facebook Investors may have suffered through the worst case of stock market "indigestion" in multiple generations between 2007 and 2009, but the subsequent bull market has produced some of the most...
F: 14.51 (-0.06), IBM: 163.07 (-10.15), GILD: 117.78 (-0.42), BAC: 18.08 (-0.04), AAPL: 130.75 (-1.32)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 117.78 (-0.42), VKTX: 6.76 (+0.12)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
Critical Alerts For Linn Energy, Gilead Sciences, BP, Alcoa and Opko Health Released By InvestorsObserver
PR Newswire - Mon Jul 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, GILD, BP, AA and OPK.
AA: 10.23 (+0.03), OPK: 16.14 (-0.20), GILD: 117.78 (-0.42), BP: 38.73 (-0.02), LINE: 6.09 (+0.06)
Research and Markets: Key Pharma News Issue - Gilead will make further oncology deals in 2015
Business Wire - Mon Jul 20, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fz2fmj/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering.
GILD: 117.78 (-0.42)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 187.07 (-0.57), GILD: 117.78 (-0.42), MRK: 58.67 (-0.33), ASPX: 100.96 (unch), NVS: 103.71 (-2.41)
Gilead's Fantastic Growth Expected To Slow
at Investor's Business Daily - Fri Jul 17, 5:48PM CDT
With nearly 400 companies in IBD's biotech industry group, it takes a lot to stand out, and Gilead Sciences (GILD) is doing that with its profit growth. The company's three-year average earnings growth rate of 74% is sixth highest, and its 2014 EPS...
GILD: 117.78 (-0.42), ABBV: 70.54 (-0.26)
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:30PM CDT
Bristol-Myers Squibb Company (BMY) announced that the European Commission has approved Evotaz.
EBIO: 2.95 (-0.04), GILD: 117.78 (-0.42), ANAC: 149.31 (+1.18), BMY: 68.87 (-1.10)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 123.98 (+1.04), AGN: 317.00 (-0.75), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), UTHR: 175.17 (-2.34), RCPT: 228.98 (+0.26), MOH: 72.56 (-0.42), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01)
Gilead Sciences (GILD) Breaks Through Resistance at $119.00
Comtex SmarTrend(R) - Thu Jul 16, 11:49AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $118.11 today and have reached the first resistance level of $119.00. Investors may be interested in a cross of the next upside pivot targets of $120.62 and $123.13.
GILD: 117.78 (-0.42)
Fitbit Leads Trio Of Hot Health-Related IPO Stocks
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
New analyst coverage and a big Celgene deal helped give a healthy boost to hot new issue Fitbit (FIT) and a pair of recent biotech IPOs Wednesday. Fitbit hit a second straight new high as it continues its hot streak. The June 18 IPO, which ran up 48%...
FIT: 46.87 (+2.40), GILD: 117.78 (-0.42), XON: 56.77 (-1.18), RCPT: 228.98 (+0.26), ABBV: 70.54 (-0.26), ENTA: 49.27 (-0.17), CELG: 136.24 (+1.01)
What Will Gilead Buy Next? 4 Possible Targets
at Investor's Business Daily - Wed Jul 15, 3:44PM CDT
Tuesday's announcement that Celgene (CELG) agreed to acquire Receptos (RCPT) pleased investors in those two stocks, but for investors in Gilead Sciences (GILD), which was rumored to be interested in Receptos, it means waiting on the edges of their...
JNJ: 100.34 (-0.03), VRTX: 130.97 (-2.50), GILD: 117.78 (-0.42), ACHN: 9.26 (-0.10), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), BMY: 68.87 (-1.10), CELG: 136.24 (+1.01)
Are Gilead Sciences, Inc.'s Expectations Too High for This Drug?
Keith Speights, The Motley Fool - Motley Fool - Wed Jul 15, 11:03AM CDT
Source: Gilead Sciences. Like the mythical King Midas, it seems that nearly everything Gilead Sciences touches turns to gold -- maybe that's where it gets its ticker symbol. The big biotech has built a juggernaut over the years from its HIV drug...
GILD: 117.78 (-0.42)
Celgene Hits High As Street Applauds Receptos Buyout
at Investor's Business Daily - Wed Jul 15, 10:12AM CDT
Celgene (CELG) stock jumped 10% to a new high above 135 Wednesday morning as it got several price-target increases in the wake of its deal to buy Receptos (RCPT). Celgene agreed to pay $7.2 billion for Receptos and announced preliminary Q2 earnings...
BIIB: 409.50 (+0.57), GILD: 117.78 (-0.42), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), LLY: 85.57 (-2.30), TEVA: 63.35 (-0.26), ARNA: 4.30 (-0.05), CELG: 136.24 (+1.01)
Stock Market News for July 15, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 9:10AM CDT
Gains in energy shares amid a rise in oil prices helped benchmarks end higher on Tuesday
JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), JPM: 69.10 (-0.16), RIG: 13.35 (unch), GILD: 117.78 (-0.42), AMGN: 163.70 (-0.64), COP: 56.49 (-0.08), XOM: 81.66 (-0.10), WFC: 57.95 (-0.10), CVX: 93.90 (+0.96), SLB: 84.30 (+0.78), CELG: 136.24 (+1.01)
